Johnson & Johnson to Acquire Proteologix for $850 Million
Slice of Healthcare Team
05/20/2024
Key Highlights
- Acquisition valued at $850 million with potential milestone payment
- Focus on bispecific antibodies for immune-mediated diseases
- Pipeline includes PX128 and PX130 for atopic dermatitis and asthma
- Strategic move to deliver high-bar efficacy and remission
Source: Business Wire
Notable Quotes
“ Integrating Proteologix bispecific antibodies into our pipeline is an important first step in fulfilling our commitment to people living with AD,” ice Long, Worldwide Vice President, Immunology at Janssen Biotech, Inc ”
Cand
“ We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease-driving pathways that are mediating the skin inflammation in heterogenous subpopulations of AD patients. ”
David Lee, Global Immunology Therapeutic Area Head at Janssen Biotech, Inc
SoHC's Take
Johnson & Johnson's acquisition of Proteologix marks a strategic enhancement of their immune-mediated disease pipeline. By integrating Proteologix's innovative bispecific antibodies, J&J positions itself to address the unmet needs in atopic dermatitis and asthma treatments. The addition of PX128 and PX130, both targeting critical disease-driving pathways, signifies a commitment to delivering superior efficacy and improving patient outcomes. This move underscores J&J's dedication to expanding their capabilities in developing targeted therapies that promise long-term remission for patients. The acquisition not only strengthens their portfolio but also sets a new benchmark in the biopharmaceutical landscape for treating complex immune-mediated conditions.
